Aurobindo Pharma Delivers Strong Q2FY27 Results With 32.5% YoY PAT Growth
Aurobindo Pharma Ltd 路 Press Release 路 05 Nov 2026, 1:33 am
Aurobindo Pharma Delivers Strong Q2FY27 Results With 32.5% YoY PAT Growth Aurobindo Pharma reported its highest-ever quarterly revenue of INR 10,263 Cr in Q2FY27, up 23.9% YoY (12.2% QoQ). EBITDA grew 28.5% YoY to INR 2,156 Cr with margins expanding 75 bps YoY to 21.0%. Net profit surged 32.5% YoY to INR 1,124 Cr. US revenue rose 25.2% YoY to INR 4,555 Cr, while Europe grew 27.5% YoY to INR 3,161 Cr. The company generated USD 146 million in free cash flow, held net cash of USD 189 million as of 30th Sep'26, and declared an interim dividend of INR 7.0 per share.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
